Researchers from University of Melbourne in Australia started by looking at a particular white blood cell - the resident memory CD8 T cells or Trms.
Located in the lungs, the Trms are excellent at protecting against different strains of flu, researchers said.
The flu vaccine most people get each year works by stimulating white blood cells to produce the antibodies to fight a specific infection, researchers said.
"We had identified a cell type that could provide great protection against different strains of influenza virus, but because they decayed so rapidly we would still have to constantly vaccinate the population," said Angela Pizzolla, research fellow at University of Melbourne.
Researchers then found a population of Trms living in nasal tissue that and unlike their counterparts in the lung, they can live for a very long time.
They tracked these cells in lung and nasal tissue and found that while a population of lung Trms cells would drop at rate of 100,000 cells down to just 1000 cells over a period of 100 days, the Trms cell population in the nasal tissue remained stable.
It also means scientists could look at developing a vaccine that stimulates these Trms in the nose, halting specific strains of virus before it even enters the respiratory system, they said.
"We basically stopped influenza at the gates," said Linda Wakim from University of Melbourne.
The influenza virus is notoriously difficult to treat and manage. It is highly contagious - meaning it is very good at spreading from person to person.
"Instead of recognising external parts of the virus, which are constantly changing, these cells are trained to recognise internal parts of the virus. These parts of the virus are equivalent to our internal organs," Wakim said.
It means a vaccine that induces flu fighting Trm cells in the nose could outwit the flu virus, researchers said.
The study was published in the journal Science Immunology.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of 5 free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app